• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于影响食管鳞状细胞癌患者根治性切除术后预后的早期复发的定义及危险因素

Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection.

作者信息

Zhang Yaowen, Gao Junhui, Zheng Anping, Yang Haijun, Li Jian, Wu Shouxin, Zhao Jiangman, Meng Peng, Zhou Fuyou

机构信息

Department of Radiation Oncology, Anyang Cancer Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, China.

Shanghai Zhangjiang Institute of Medical Innovation, Biotecan Pharmaceuticals co., ltd., Shanghai 201204, China.

出版信息

Transl Oncol. 2021 Jun;14(6):101066. doi: 10.1016/j.tranon.2021.101066. Epub 2021 Mar 18.

DOI:10.1016/j.tranon.2021.101066
PMID:33744728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7985560/
Abstract

Early recurrence after surgery could affect cancerous patients' prognosis, but the definition of early recurrence and its risk factors for esophageal squamous cell carcinoma (ESCC) patients are still unclear. This study analyzed the clinical data of 468 post-surgery recurrent ESCC patients retrospectively. A minimum p-value approach was used to evaluate the optimal cut-off value of recurrence free survival (RFS) to define early recurrence. Risk factors of early recurrence were developed based on a Cox model. The optimal cut-off value of RFS to distinguish early recurrence was 21 months (p <0.001). Independent risk factors for early recurrence included tumor locations (HR=0.562, p <0.001), pathological T stage (HR=1.829, p <0.001), tumor diameter (HR=1.344, p = 0.039), positive lymph nodes (HR=1.361, p <0.001), and total resected lymph nodes (HR=1.271, p = 044). For the late recurrent patients, there was a much more significant survival advantage for recurrence after concurrent chemoradiotherapy than that after sequential chemoradiotherapy and radiotherapy alone (p = 0.0066). In conclusion, this study defined 21 months of RFS as early recurrence and also identified its risk factors. Concurrent chemoradiotherapy was suggested as preferred post-relapse treatment for late recurrent ESCC patients.

摘要

手术后的早期复发会影响癌症患者的预后,但食管鳞状细胞癌(ESCC)患者早期复发的定义及其危险因素仍不明确。本研究回顾性分析了468例手术后复发的ESCC患者的临床资料。采用最小p值法评估无复发生存期(RFS)的最佳临界值以定义早期复发。基于Cox模型确定早期复发的危险因素。区分早期复发的RFS最佳临界值为21个月(p<0.001)。早期复发的独立危险因素包括肿瘤位置(HR=0.562,p<0.001)、病理T分期(HR=1.829,p<0.001)、肿瘤直径(HR=1.344,p=0.039)、阳性淋巴结(HR=1.361,p<0.001)和切除的淋巴结总数(HR=1.271,p=0.044)。对于晚期复发患者,同步放化疗后复发的生存优势比序贯放化疗和单纯放疗后复发更为显著(p=0.0066)。总之,本研究将21个月的RFS定义为早期复发,并确定了其危险因素。建议同步放化疗作为晚期复发ESCC患者复发后的首选治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/9c8e7739329b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/6b31910ee090/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/80f5c6a43401/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/ac6733af2ff4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/4aef21dc7c34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/9c8e7739329b/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/6b31910ee090/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/80f5c6a43401/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/ac6733af2ff4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/4aef21dc7c34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30b/7985560/9c8e7739329b/gr5.jpg

相似文献

1
Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection.基于影响食管鳞状细胞癌患者根治性切除术后预后的早期复发的定义及危险因素
Transl Oncol. 2021 Jun;14(6):101066. doi: 10.1016/j.tranon.2021.101066. Epub 2021 Mar 18.
2
A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.局部晚期食管鳞状细胞癌术后放疗的回顾性研究。
Ann Palliat Med. 2019 Nov;8(5):708-716. doi: 10.21037/apm.2019.11.19.
3
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.根治性切除术后淋巴结复发的挽救性治疗。
Radiat Oncol. 2019 Sep 18;14(1):169. doi: 10.1186/s13014-019-1377-y.
4
[Predictive value of log odds of positive lymph nodes for the prognosis of patients with node-negative squamous cell carcinoma of the thoracic esophagus after radical esophagectomy].[阳性淋巴结对数比对于胸段食管鳞癌根治性食管切除术后淋巴结阴性患者预后的预测价值]
Zhonghua Wei Chang Wai Ke Za Zhi. 2016 May;19(5):535-9.
5
Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.内镜下切除黏膜下食管鳞癌后行食管切除术与放化疗的长期疗效比较。
Dis Esophagus. 2019 Dec 31;32(12). doi: 10.1093/dote/doz023.
6
Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.胸段食管鳞癌患者术后复发模式及复发后挽救性治疗的疗效。
BMC Cancer. 2020 Feb 22;20(1):144. doi: 10.1186/s12885-020-6622-0.
7
[Associated factors of postoperative relapse and metastasis in pT1bN0M0-pT4aN0M0 thoracic esophageal squamous cell carcinoma].[pT1bN0M0 - pT4aN0M0期胸段食管鳞状细胞癌术后复发和转移的相关因素]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Sep 25;20(9):1045-1049.
8
Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.根治性放化疗或单纯放疗后复发的食管鳞癌行挽救性放化疗与挽救性手术的比较。
Dis Esophagus. 2014 Feb-Mar;27(2):134-40. doi: 10.1111/j.1442-2050.2012.01440.x. Epub 2012 Oct 22.
9
The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma.辅助治疗对可切除的 IIa-IVa 期胸下段食管鳞癌患者生存和复发模式的影响。
World J Surg Oncol. 2018 Nov 7;16(1):216. doi: 10.1186/s12957-018-1516-1.
10
Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.三模态治疗后病理完全缓解的食管鳞癌复发的危险因素。
Anticancer Res. 2020 Aug;40(8):4387-4394. doi: 10.21873/anticanres.14442.

引用本文的文献

1
Development and Validation of a Predictive Nomogram for Early Postoperative Recurrence in Non-Small Cell Lung Cancer.非小细胞肺癌术后早期复发预测列线图的开发与验证
Med Sci Monit. 2025 Jul 13;31:e948441. doi: 10.12659/MSM.948441.
2
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study.新辅助免疫化疗及食管切除术后辅助免疫治疗食管鳞状细胞癌:一项真实世界研究
Front Immunol. 2024 Dec 17;15:1456193. doi: 10.3389/fimmu.2024.1456193. eCollection 2024.
3
Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma: a Dual-Center Retrospective Cohort Study.
新辅助治疗的食管和食管胃腺癌早期复发的定义及预测因素:一项双中心回顾性队列研究
Ann Surg Oncol. 2025 Mar;32(3):1617-1627. doi: 10.1245/s10434-024-16403-5. Epub 2024 Nov 5.
4
Interval to Recurrence Affects Survival in Recurrent Head and Neck Squamous Cell Carcinoma.复发间隔影响复发性头颈部鳞状细胞癌的生存。
Cancer Diagn Progn. 2024 Sep 1;4(5):658-666. doi: 10.21873/cdp.10378. eCollection 2024 Sep-Oct.
5
Association of the Scottish inflammatory prognostic score with treatment-related adverse events and prognosis in esophageal cancer receiving neoadjuvant immunochemotherapy.苏格兰炎症预后评分与接受新辅助免疫化疗的食管癌患者治疗相关不良事件和预后的关系。
Front Immunol. 2024 Jul 5;15:1418286. doi: 10.3389/fimmu.2024.1418286. eCollection 2024.
6
Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study.根治性手术后中胸段食管癌淋巴结复发模式及放疗野划定指南的探索:一项真实世界研究。
BMC Cancer. 2024 May 16;24(1):596. doi: 10.1186/s12885-024-12297-4.
7
Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.淋巴结阳性食管鳞癌术后复发的分子和免疫学特征。
Cancer Med. 2024 May;13(9):e7228. doi: 10.1002/cam4.7228.
8
Significance of intratreatment tumor volume change during chemoradiotherapy for potentially resectable thoracic esophageal squamous cell carcinoma.对于潜在可切除的胸段食管鳞状细胞癌,同步放化疗期间肿瘤体积变化的意义。
Am J Transl Res. 2022 Jul 15;14(7):4776-4785. eCollection 2022.
9
Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.局部晚期食管鳞癌同步放化疗患者总生存预测列线图的建立与验证。
Biomed Res Int. 2022 Jul 14;2022:6455555. doi: 10.1155/2022/6455555. eCollection 2022.